DelfaGLP-1 Atlas

Lead sponsor

University of Texas Southwestern Medical Center

9 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

9

Trials led

4

Active

747

Total enrollment

7

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 2
1
Phase 2/3
1
Phase 4
5
Not applicable
2

Trials by status

Recruiting
2
Active, not recruiting
2
Completed
3
Terminated
1
Withdrawn
1

Trials led

Impact of Liraglutide 3.0 on Body Fat DistributionBMI ≥30Ph 4Completed235
SIMPLEHbA1c ≥10%Ph 4Completed157
TEXPEFBMI ≥28Ph 2/3Recruiting120
IMPACT-MACSBMI ≥27not applicableRecruiting75
Tirzepatide for Obesity and Meth Use Disorder—Ph 2Active, not recruiting45
DIALYSIS-TIR Study—Ph 4Active, not recruiting43
Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation—not applicableTerminated39
Demonstrate the Effects of Pramlintide on Weight Reduction in SchizophreniaBMI ≥27Ph 4Completed33
Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 DiabetesHbA1c ≥7%Ph 4Withdrawnnot disclosed